Kinetic analysis of saturable myocardial uptake of idarubicin in rat heart: Effect of doxorubicin and hypothermia

Pharmaceutical Research

Volumn 20, Issue 1, 2003, Pages 58-63

  Kang, Wonku ^a   Weiss, Michael ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Doxorubicin; Heart; Hypothermia; Idarubicin; Saturable uptake

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; DOXORUBICIN; IDARUBICIN; IDARUBICINOL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG TISSUE LEVEL; DRUG UPTAKE; EFFUSION; HEART MUSCLE; HYPOTHERMIA; INFUSION; ISOLATED HEART; MALE; NONHUMAN; NONLINEAR REGRESSION ANALYSIS; PRIORITY JOURNAL; RAT;

ANIMALS; DOXORUBICIN; DRUG INTERACTIONS; HEART; HYPOTHERMIA, INDUCED; IDARUBICIN; MALE; MODELS, BIOLOGICAL; MYOCARDIUM; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0037261372     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022246708326     Document Type: Article

References (26)

1. G. Speelmans, R. W. Staffhorst, H. G. Steenbergen, and B. de Kruijff. Transport of the anti-cancer drug doxorubicin across cytoplasmic membranes and membranes composed of phospholipids derived from Escherichia coli occurs via a similar mechanism. Biochim. Biophys. Acta 1284:240-246 (1996).
2. 1 kidney epithelial cell line. J. Pharmacol. Exp. Ther. 286:525-530 (1998).
3. P. R. Wielinga, H. V. Westerhoff, and J. Lankelma. The relative importance of passive and P-glycoprotein mediated anthracycline efflux from multidrug-resistant cells. Eur. J. Biochem. 267:649-657 (2000).
4. M. Weiss and W. Kang. P-glycoprotein inhibitors enhance saturable uptake of idarubicin in rat heart: Pharmacokinetic/pharmacodynamic modeling. J. Pharmacol. Exp. Ther. 300:688-694 (2002).
5. A. W. El-Kareh and T. W. Secomb. A mathematical model for comparison of bolus injection, continuous infusion, and liposomal delivery of doxorubicin to tumor cells. Neoplasia 2:325-338 (2000).
6. M. Weiss. Pharmacokinetics in organs and the intact body: model validation and reduction. Eur. J. Pharm. Sci. 7:119-127 (1998).
7. R. Danesi, A. Paparelli, N. Bernardini, and M. Del Tacca. Cytofluorescence localization and disposition of doxorubicin and doxorubicinol in rat cardiac tissue. Eur. J. Cancer Clin. Oncol. 24:1123-1131 (1988).
8. W. Kang and M. Weiss. Influence of P-glycoprotein modulators on cardiac uptake, metabolism, and effects of idarubicin. Pharm. Res. 18:1535-1541 (2001).
9. J. A. Jacquez and T. Perry. Parameter estimation: local identifiability of parameters. Am. J. Physiol. 258:E727-E736 (1990).
10. D. Z. D'Argenio and A. Schumitzky. ADAPT II User's guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software. Biomedical Simulations Resource, Los Angeles, California, 1997.
11. G. A. F. Seber and C. J. Wild. Nonlinear Regression, John Wiley, New York, 1989, pp 21-42.
12. S. Huet, A. Bouvier, M.-A. Gruet, and E. Jolivet. Statistical Tools for Nonlinear Regression. Springer, New York, 1996, pp. 69-70.
13. K. Nagasawa, N. Ohnishi, and T. Yokoyama. Transport mechanisms of idarubicin, an anthracycline derivative, in human leukemia HL60 cells and mononuclear cells, and comparison with those of its analogs. Jpn. J. Cancer Res. 88:750-759 (1997).
14. C. Peterson and A. Trouet. Transport and storage of daunorubicin and doxorubicin in cultured fibroblasts. Cancer Res. 38:4645-4649 (1978).
15. S. Nagaoka, S. Kawasaki, K. Sasaki, and T. Nakanishi. Intracellular uptake, retention and cytotoxic effect of adriamycin combined with hyperthermia in vitro. Jpn. J. Cancer Res. 77:205-211 (1986).
16. D. A. Bates and W. J. Mackillop. Hyperthermia, adriamycin transport, and cytotoxicity in drug-sensitive and -resistant Chinese hamster ovary cells. Cancer Res. 46:5477-5481 (1986).
17. Y. Liu, C.-W. Cho, X. Yan, T. K. Henthorn, K. O. Lillehei, W. N. Cobb, and K. Y. Ng. Ultrasound-induced hyperthermia increases cellular uptake and cytotoxicity of P-glycoprotein substrates in multi-drug resistant cells. Pharm. Res. 18:1255-1261 (2001).
18. J. Weisser, J. Martin, E. Bisping, L. S. Maier, F. Beyersdorf, G. Hasenfuss, and B. Pieske. Influence of mild hypothermia on myocardial contractility and circulatory function. Basic Res. Cardiol. 96:198-205 (2001).
19. M. Sasaya, I. Wada, M. Shida, M. Sato, Y. Hatakeyama, H. Saitoh, and M. Takada. Uptake of doxorubicin by cultured kidney epithelial cells LLC-PK1. Biol. Pharm. Bull. 21:527-529 (1998).
20. R. Regev and G. D. Eytan. Flip-flop of doxorubicin across erythrocyte and lipid membranes. Biochem. Pharmacol. 54:1151-1158 (1997).
21. S. Voswinkel, C. W. M. Haest, and B. Deuticke. Complex effects of papain on function and inhibitor sensitivity of the red cell anion exchanger AE1 suggest the presence of different transport subsites. J. Membr. Biol. 179:205-221 (2001).
22. P. Lu, R. Liu, and F. J. Sharom. Drug transport by reconstituted P-glycoprotein in proteoliposomes. Effect of substrates and modulators, and dependence on bilayer phase state. Eur. J. Biochem. 268:1687-1697 (2001).
23. G. D. Eytan and P. W. Kuchel. Mechanism of action of P-glycoprotein in relation to passive membrane permeation. Int. Rev. Cytol. 190:175-250 (1999).
24. Y. Chen, A. C. Pant, and S. M. Simon. P-glycoprotein does not reduce substrate concentration from the extracellular leaflet of the plasma membrane in living cells. Cancer Res. 61:7763-7769 (2001).
25. J. Lankelma, R. Fernandez Luque, H. Dekker, W. Schinkel, and H. M. Pinedo. A mathematical model of drug transport in human breast cancer. Microvasc. Res. 59:149-161 (2000).
26. S. S. Bielack, R. Erttmann, B. Kempf-Bielack, and K. Winkler. Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties? Eur. J. Cancer A32:1652-1660 (1996).